Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach